News
Clinical phase III studies of Lu AA21004 presented for the first time at the 2011 Annual Meeting
H. Lundbeck A/S announced the presentation of new data from the clinical phase III program of Lu AA21004, an investigational compound for the treatment of adult patients with major depressive disorder (MDD), at the 2011 Annual Meeting of the...
News
Mylan Launches Generic Version of Percodan Tablets
Mylan Inc. announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Oxycodone and Aspirin Tablets USP, 4.8355 mg/325 mg, based on an agreement with licensing partner Coastal Pharmaceuticals. This product is the generic version of Endo Pharmaceuticals' Percodan® Tablets,...
News
Sun Pharma announces USFDA approval for DOCEFREZTM for Injection
Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its New Drug Application (NDA) for DOCEFREZTM (docetaxel) for Injection, 20 mg/vial and 80 mg/vial. This NDA provides for...
News
Almac Introduces selectAZyme
Almac’s biocatalysis business has expanded from its 2009 launch with the sale of six enzyme screening kits, to the current supply of 100s of kgs of chiral intermediates for drug substance manufacture, regular enzyme supply to specialty chemical...
News
Seattle Genetics Announces Approval For FDA Accepts Brentuximab Vedotin BLAs
Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration has accepted for filing two Biologics License Applications (BLAs) for brentuximab vedotin, including one for the treatment of patients with relapsed or refractory Hodgkin lymphoma and one for...
News
Teva to Acquire Cephalon in $6.8 Billion Transaction
Teva Pharmaceutical Industries Ltd. and Cephalon, Inc.announced that their Boards of Directors have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total...
News
Ranbaxy Launches Generic Olanzapine Tablets in Spain
Ranbaxy Laboratories Limited announced the Day-1 launch of Olanzapine Tablets, the generic version of Zyprexa. Ranbaxy will be introducing Olanzapine tablets 2.5mg, 5mg, 7.5mg and 10mg and also orodispersables in 5mg and 10mg. Zyprexa is the innovator product of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
